<DOC>
	<DOCNO>NCT00006387</DOCNO>
	<brief_summary>RATIONALE : Vaccines may make body build immune response kill tumor cell . QS21 may improve ability immune system respond disease . Combining vaccine therapy QS21 may kill tumor cell . PURPOSE : Phase I trial study effectiveness vaccine therapy plus QS21 treat patient advanced pancreatic colorectal cancer .</brief_summary>
	<brief_title>Vaccine Therapy Plus QS21 Treating Patients With Advanced Pancreatic Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine toxicity ra peptide cancer vaccine plus immunological adjuvant QS21 patient advance pancreatic colorectal adenocarcinoma . II . Determine immunologic effect treatment regimen patient . III . Determine antitumor effect treatment regimen patient . OUTLINE : This dose escalation study ras peptide cancer vaccine . Patients receive ra peptide cancer vaccine mixed immunological adjuvant QS21 subcutaneously monthly 4 dos , every 2 month 4 dos , every 4 month 3 dos , every 6 month 2 dos , annually thereafter absence unacceptable toxicity . Cohorts 3 6 patient receive escalate dos ras peptide cancer vaccine maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 2 3 2 4 patient experience dose limit toxicity . PROJECTED ACCRUAL : Approximately 15-20 patient accrue study within 30 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>QS 21</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm advanced pancreatic colorectal adenocarcinoma Curatively unresectable OR Recurrent follow potentially curable resection OR Pancreatic adenocarcinoma surgically resect within past 12 month Must one follow ras gene mutation codon 12 : Glycine cysteine Glycine aspartic acid Glycine valine HLA A2 require evidence HLA restriction peptide presentation PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 3 month Hematopoietic : WBC least 3,500/mm3 Lymphocyte count least 500/mm3 Hepatic : Bilirubin great 3 mg/dL Renal : Creatinine great 2 time upper limit normal OR Creatinine clearance least 50 mL/min Other : No active infection require sytemic therapy No history severe allergy anaphylaxis No immunodeficiency ( e.g. , HIV infection , lupus , myeloma ) Not pregnant Negative pregnancy test Fertile patient must use effective contraception Women must use contraception 3 month prior , 3 month study Men must use contraception 3 month study PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunologic therapy No concurrent systemic immunotherapy cancer Chemotherapy : At least 4 week since prior chemotherapy No concurrent systemic chemotherapy cancer Endocrine therapy : At least 4 week since prior corticosteroid No concurrent corticosteroid Radiotherapy : At least 4 week since prior radiotherapy Surgery : See Disease Characteristics Other : At least 4 week since prior immunosuppressant ( e.g. , methotrexate ) No concurrent immunosuppressant Concurrent nonsteroidal antiinflammatory drug pain palliation allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
	<keyword>adenocarcinoma pancreas</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>